These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17569043)

  • 1. A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
    Stadler WM; Desai AA; Quinn DI; Bukowski R; Poiesz B; Kardinal CG; Lewis N; Makalinao A; Murray P; Torti FM
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):689-94. PubMed ID: 17569043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.
    Shibata SI; Doroshow JH; Frankel P; Synold TW; Yen Y; Gandara DR; Lenz HJ; Chow WA; Leong LA; Lim D; Margolin KA; Morgan RJ; Somlo G; Newman EM
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1149-55. PubMed ID: 19322566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer.
    Sridhar SS; Canil CM; Chi KN; Hotte SJ; Ernst S; Wang L; Chen EX; Juhasz A; Yen Y; Murray P; Zwiebel JA; Moore MJ
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):927-33. PubMed ID: 20602233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma.
    Pagliaro LC; Perez CA; Tu SM; Daliani DD
    Urol Oncol; 2006; 24(6):487-91. PubMed ID: 17138128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma.
    Ellerhorst JA; Sella A; Amato RJ; Tu SM; Millikan RE; Finn LD; Banks M; Logothetis CJ
    Cancer; 1997 Dec; 80(11):2128-32. PubMed ID: 9392335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
    Masuda N; Taguchi T; Nakayama T; Shiba E; Watatani M; Kurebayashi J; Takatsuka Y; Sakamoto J; Noguchi S;
    Cancer Chemother Pharmacol; 2008 May; 61(6):989-95. PubMed ID: 17641893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
    Harshman LC; Li M; Srinivas S
    Am J Clin Oncol; 2008 Oct; 31(5):417-23. PubMed ID: 18838876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy.
    Petrioli R; Paolelli L; Francini E; Marsili S; Pascucci A; Sciandivasci A; de Rubertis G; Barbanti G; Manganelli A; Salvestrini F; Francini G
    Anticancer Drugs; 2007 Aug; 18(7):817-20. PubMed ID: 17581304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
    Padrik P; Leppik K; Arak A
    Urol Oncol; 2004; 22(5):387-92. PubMed ID: 15464918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
    O'connor T; Rustum Y; Levine E; Creaven P
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
    Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
    J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity.
    Segota E; Mekhail T; Olencki T; Hutson TE; Dreicer R; Wacker B; Osterwalder B; Elson P; Zhou M; Bukowski RM
    Urol Oncol; 2007; 25(1):46-52. PubMed ID: 17208138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer.
    Amato RJ; Mohammad T
    J Exp Ther Oncol; 2008; 7(1):41-7. PubMed ID: 18472641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma.
    Tsimafeyeu I; Demidov L; Kharkevich G; Petenko N; Galchenko V; Sinelnikov I; Naidzionak U
    Am J Clin Oncol; 2012 Jun; 35(3):251-4. PubMed ID: 21358295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
    Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
    Perotti A; Locatelli A; Sessa C; Hess D; Viganò L; Capri G; Maur M; Cerny T; Cresta S; Rojo F; Albanell J; Marsoni S; Corradino I; Berk L; Rivera VM; Haluska F; Gianni L
    J Clin Oncol; 2010 Oct; 28(30):4554-61. PubMed ID: 20855840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
    Amato RJ; Morgan M; Rawat A
    Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.